Physician profile

Brandy M Millay

Family · Winchester, VA

NPI 1548664360

$457.93

in general payments reported to CMS, 2019-2025

10 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$131.96

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Lilly USA, LLC $155.62 2022-2023 Trulicity, Mounjaro
Abbvie INC. $143.33 2022-2023
Pfizer INC. $36.11 2023-2024
Astrazeneca Pharmaceuticals LP $26.07 2023 Breztri
Organon LLC $24.55 2023 Nexplanon
Novo Nordisk INC $16.35 2022
Boehringer Ingelheim Pharmaceuticals, INC. $16.10 2022
Glaxosmithkline, LLC. $15.66 2022
Amgen INC. $14.09 2022
Dynavax Technologies Corporation $10.05 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Brandy M Millay

$457.93

in general payments reported 2019-2025

Years
2022-2024
Top company
Lilly USA, LLC

https://glasscript.com/doctor/11234138/brandy-m-millay

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.